Medical device company Penumbra (NYSE:PEN) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up ...

is a very severe neurological disease with a high mortality rate and poor clinical outcomes. In this study, we compared our experience of mechanical thrombectomy using the Solitaire stent (Solitaire ...

Looking back on medical devices & supplies - cardiology, neurology, vascular stocks’ Q3 earnings, we examine this quarter’s ...

Apr. 16, 2024 — Patients with suspected inflammatory bowel disease (IBD) could benefit from better testing protocols that would reduce the need and lengthy wait for potentially unnecessary ...

Looking back on medical devices & supplies - cardiology, neurology, vascular stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Penumbra (NYSE:PEN) and its peers.

Penumbra leads the way with revolutionary advancements like computer assisted vacuum thrombectomy (CAVT) by maintaining an unrelenting commitment to creating the best technology for peripheral and ...

Penumbra leads the way by maintaining an unrelenting commitment to creating the best technology for neurovascular interventions with a focus on what is impactful to patients and physicians.

Dr. Kakarla, an interventional radiologist at Javon Bea Hospital in Rockford, Illinois, continued, “Penumbra’s continuous advancements provide a comprehensive portfolio for physicians to treat a wider ...

27, 2025 — Heart disease remains the leading cause of death in the ... Study Shows Anti-Clotting Drug Reduced Bleeding Events in Patients With Atrial Fibrillation Jan. 23, 2025 — Researchers ...

Microbiota-based interventions, such as promoting the growth of beneficial short-chain fatty acid–producing bacteria that are reduced during the acute phase of the disease, may benefit patients with ...